Gene splicing refers to two related but distinct processes. In molecular biology, it describes the natural editing step inside your cells where stretches of non-coding sequence are cut out of a freshly copied RNA molecule and the remaining coding segments are stitched together to form a finished message that can be read into protein. In biotechnology and popular usage, “gene splicing” often means the laboratory technique of cutting and recombining DNA from different sources. Both processes involve precision cutting and joining of genetic material, but the natural version happens trillions of times a day in your body without any human intervention, and it is far more intricate than most people realize.
How the Spliceosome Removes Introns
When a gene is first copied into RNA, the resulting transcript is a rough draft. It contains protein-coding segments called exons interspersed with non-coding stretches called introns. Before the cell can use that RNA to build a protein, the introns have to be cut out and the exons joined together. This removal-and-joining step is what biologists mean by pre-mRNA splicing, and it is carried out by a massive molecular machine called the spliceosome.
The spliceosome is one of the most complex machines in the cell. It is built from five small RNA molecules and well over a hundred proteins that assemble fresh on each intron, do their work, and then disassemble. The cutting happens through two precise chemical reactions. In the first, a specific point inside the intron loops back and attacks the junction at the start of the intron, severing the upstream exon and forming a lasso-shaped loop called a lariat. In the second step, the freed upstream exon attacks the junction at the end of the intron, joining the two exons together and releasing the lariat for recycling.1PubMed. CryoEM structures of spliceosomal complexes reveal the molecular mechanism of pre-mRNA splicing The result is a mature messenger RNA with an uninterrupted coding sequence, ready to be translated into protein.
At the heart of this process, two of the spliceosome’s small RNAs fold together to form a catalytic core that positions the intron precisely at a pair of metal ions. Those metal ions are what actually drive the chemistry. The branch-point nucleotide deep inside the intron attacks the upstream splice site first, and then the newly freed exon end attacks the downstream splice site to complete the join.2PubMed. RNA Splicing by the Spliceosome Structural studies have captured the spliceosome frozen at different stages of this cycle, showing how the lariat forms and how the freed exon stays tethered in place so the second reaction can proceed accurately.3PubMed. Structure of a yeast catalytic step I spliceosome at 3.4 Å resolution
A Second, Rarer Splicing System
Most introns in the human genome are handled by the major spliceosome described above, but a small minority belong to a different class. These rare introns are recognized and removed by a separate machine called the minor spliceosome, which uses its own set of small RNAs. Despite accounting for fewer than one percent of all introns, the genes that contain them often perform essential functions, so the minor spliceosome punches well above its weight in biological importance.
Structural work on the activated human minor spliceosome has revealed how its small RNAs recognize the distinct sequence signals of these rare introns. The splice site and branch-point sequence of the intron are read by counterpart RNAs specific to the minor system.4PubMed. Structure of the activated human minor spliceosome Detailed analysis of one of those RNA components has uncovered a two-part recognition strategy, where the intron’s starting sequence is read partly through standard base pairing and partly through an unusual interaction with a stem-loop structure in the RNA itself.5Molecular Cell. Structure of the U11 snRNP and mechanism of U12-type 5′ splice site recognition The existence of two parallel splicing systems in one cell hints at how deeply embedded this process is in the architecture of complex life.
Alternative Splicing and Protein Diversity
If every gene were spliced the same way every time, each gene would produce exactly one protein. That is not what happens. Through a process called alternative splicing, different combinations of exons can be included or excluded from the final message, so a single gene can give rise to multiple distinct protein variants. These variants can differ in which functional regions they carry, where they end up inside the cell, or how they interact with other molecules.6PubMed Central. Alternative splicing generates HER2 isoform diversity underlying antibody-drug conjugate resistance in breast cancer
This is a big part of how roughly 20,000 human genes manage to produce a much larger repertoire of proteins. Alternative splicing allows a protein-coding gene to generate more than one mature transcript, and each of those transcripts can encode a protein that has gained or lost specific functional domains.7PubMed Central. Re-evaluating the impact of alternative RNA splicing on proteomic diversity The classic example is a cell-surface receptor that exists in a membrane-anchored form and a secreted form, produced from the same gene by including or skipping the exon that codes for the membrane anchor.
Alternative splicing patterns vary dramatically between tissues. When researchers looked for tissue-specific splicing at the protein level, nervous tissues stood out. The frontal cortex had the most tissue-specific splicing events of any individual tissue, and when tissues were grouped by organ system, the nervous system accounted for more than half of all group-specific events.8PubMed Central. An analysis of tissue-specific alternative splicing at the protein level Heart tissue also showed a high number of unique splicing patterns. This means the brain and the heart are running their own customized versions of many shared genes, which helps explain the specialized functions of those organs without requiring entirely separate gene sets.
Newer approaches combining machine learning with targeted sequencing are still uncovering previously undetected tissue-specific splicing events, even in well-studied datasets, suggesting the full landscape of alternative splicing is larger than current catalogs reflect.9PubMed Central. Machine learning-optimized targeted detection of alternative splicing
What Steers Splicing Decisions
If the spliceosome can choose different exon combinations, something has to tell it which combination to use in a given cell at a given time. That guidance comes from a network of regulatory proteins and signals layered on top of the core machinery.
Two major families of regulatory proteins do much of the steering. One family, called SR proteins, generally promotes the inclusion of specific exons by binding to short sequence motifs in the RNA. The other family, called hnRNPs, tends to encourage exon skipping. These regulators have diversified over evolutionary time through gene duplication, producing a varied toolkit that lets multicellular organisms fine-tune splicing in a cell-type-specific way.10PubMed Central. Evolution of SR protein and hnRNP splicing regulatory factors The balance between activating and repressing signals at any given exon determines whether that exon ends up in the final message.
Splicing decisions are also shaped by the act of transcription itself. The enzyme that copies DNA into RNA does not simply hand off a finished transcript; splicing frequently begins while the RNA is still being written. This co-transcriptional splicing is more efficient than splicing that happens after the transcript is complete.11PubMed Central. Pre-mRNA splicing and its cotranscriptional connections The transcription enzyme physically interacts with spliceosome components during elongation, creating a direct link between how fast or slowly a gene is being copied and which splicing choices get made.12PubMed Central. RNA Polymerase II Phosphorylated on CTD Serine 5 Interacts with the Spliceosome during Co-transcriptional Splicing
On top of all this, chemical marks on DNA and on the proteins that package it can influence splicing outcomes. DNA methylation and histone modifications both play a role, linking the cell’s broader gene-regulation system to the fine-grained control of exon inclusion.13PubMed Central. Epigenetic regulation of alternative splicing Even environmental stress matters: heat shock and other cellular stresses can shut down normal splicing, and the mechanisms that block routine splicing appear to differ from those that alter alternative splicing during recovery, giving the cell a way to reshape its protein output in response to danger.14PubMed. Cellular stress and RNA splicing
When Splicing Goes Wrong
Because splicing depends on precise sequence signals at the boundaries of every intron, even a single-letter change in DNA can throw the process off. Mutations at splice sites or in the regulatory sequences that guide the spliceosome can cause introns to be retained, exons to be skipped, or hidden “cryptic” splice sites to be activated, producing abnormal proteins or no functional protein at all.15PubMed Central. Splicing mutations in human genetic disorders: examples, detection, and confirmation Roughly fifteen percent of all inherited single-gene disorders are caused by splicing defects of this kind.16PubMed Central. Normal and abnormal mechanisms of gene splicing and relevance to inherited skin diseases
Cancer adds another dimension. Rather than inheriting a splice-site mutation, tumor cells frequently acquire new mutations in the genes that encode the splicing machinery itself. Recurrent mutations in core splicing factors, particularly one called SF3B1, are drivers of multiple cancer types.17PubMed Central. SF3B1: from core splicing factor to oncogenic driver Mutations in other splicing components such as U2AF1 and SRSF2 similarly alter how splice sites are recognized and can serve as distinctive molecular signatures useful for diagnosis and prognosis.18PubMed Central. Unlocking the undruggable spliceosome: generative AI and structural dynamics in cancer therapy Because these mutations change splice-site selection across many genes at once, they can rewire entire networks of protein variants, pushing cells toward uncontrolled growth.19Molecular Cell. Mechanistic and functional consequences of RNA splicing alterations in cancer
Medicines That Fix Faulty Splicing
The fact that disease can result from bad splicing decisions opens the door to therapies that redirect splicing toward healthier outcomes. The most striking success story so far involves spinal muscular atrophy (SMA), a devastating neuromuscular disease. Patients with SMA lack a functional copy of a gene called SMN1 but carry a backup gene, SMN2, that is almost identical. The problem is that SMN2 routinely skips a critical exon during splicing, producing a truncated protein that degrades quickly. Understanding how that exon-skipping decision is made allowed researchers to develop drugs that coax the spliceosome into including the missing exon, restoring production of the full-length protein.20PubMed Central. Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy
Two broad strategies have reached patients. One uses short synthetic RNA molecules called antisense oligonucleotides that bind to the pre-mRNA near the skipped exon and physically block the signals that cause it to be left out. The other uses small-molecule drugs taken by mouth. Risdiplam, the first approved small-molecule splicing modifier, established proof of concept that a pill could change a splicing decision inside neurons throughout the body.21PubMed Central. Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines Research is now exploring combination approaches, showing that low doses of an antisense oligonucleotide paired with a small molecule can produce a synergistic boost in exon inclusion in patient cells.22PubMed Central. Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene
The molecular details are still being worked out. Recent experiments have found that how these small molecules interact with the spliceosome is more context-dependent than initially thought. One of the spliceosome’s own protein components can either help or hinder drug binding depending on the local RNA environment, and risdiplam appears to require additional cellular factors that are not needed by a related compound, branaplam.23PubMed Central. The U1 snRNP protein U1C and Helix H of U1 snRNA are critical for small molecule splicing modulator function Understanding those differences matters for designing the next generation of splicing-targeted drugs for other diseases.
Ancient Origins of the Splicing System
The spliceosome did not appear from nowhere. Its likely ancestors are self-splicing genetic elements called group II introns, which are found in bacteria and in the genomes of mitochondria and chloroplasts. Group II introns are mobile stretches of RNA that can cut themselves out of a transcript, form a lariat, and even insert themselves into new locations in DNA.24PubMed Central. Group II introns: mobile ribozymes that invade DNA The parallels are striking: both group II introns and the spliceosome use a lariat intermediate, both rely on a metal-ion-containing active site in the RNA itself, and both carry out two sequential cutting-and-joining reactions.25PubMed. Group II Intron Self-Splicing
The leading hypothesis is that group II introns invaded the genome of an early eukaryotic ancestor, and over time their self-splicing RNA components were parceled out into the small RNAs of the spliceosome while their protein components evolved separately. This would explain why the catalytic heart of the spliceosome is still made of RNA rather than protein, a leftover from an era when these elements ran the show on their own.
Once introns were present in genes, they created an opportunity for exon shuffling, where exons from different genes can be recombined to create new proteins with novel domain combinations. Analysis of large gene databases has estimated that at least nineteen percent of exons show signatures of having been involved in exon shuffling.26PubMed. Intron phase correlations and the evolution of the intron/exon structure of genes This mechanism played a particularly important role in building the proteins that allow animal cells to stick to each other and to their surroundings, the molecular glue that makes complex multicellular body plans possible.27PubMed Central. Exon Shuffling Played a Decisive Role in the Evolution of the Genetic Toolkit for the Multicellular Body Plan of Metazoa
Circular RNAs and Backsplicing
The spliceosome’s flexibility extends to some genuinely unexpected products. In a process called backsplicing, a downstream splice site joins to an upstream splice site instead of following the normal left-to-right order. The result is a circular RNA, a closed loop with no free ends. These molecules are unusually stable because the cellular machinery that degrades linear RNA cannot get a grip on them.28PubMed Central. Molecular basis of backsplicing regulation and its application to manipulate circRNA levels
Circular RNAs were once dismissed as splicing errors, but they are now known to accumulate in specific tissues, particularly in the brain, and to play roles in gene regulation. Some act as sponges that soak up regulatory molecules, while others may be translated into small proteins. Researchers are actively working on ways to manipulate backsplicing, both to study what individual circular RNAs do and to explore their potential as tools in medicine. The discovery of circular RNAs expanded the picture of what splicing can produce beyond the simple linear-message-to-protein pipeline.
Gene Splicing in the Laboratory
Outside the cell, the phrase “gene splicing” has long been used colloquially to describe recombinant DNA technology: the practice of cutting DNA from one organism and joining it into the DNA of another. Traditional approaches use restriction enzymes to cut DNA at specific sequences and ligases to paste the pieces together, or rely on cellular recombination machinery to swap matching stretches of DNA.29PubMed Central. DNA ‘Breathing’ Recombination Cloning: A Mismatch-Tolerant, Temperature-Dependent Homologous Recombination Cloning Method These methods have been used for decades to produce everything from insulin-producing bacteria to genetically modified crops.
Newer gene-editing tools have blurred the line between laboratory “gene splicing” and the cell’s own splicing machinery. CRISPR-based editors, for example, can now be aimed at the very splice-site signals that the spliceosome reads. In one recent demonstration targeting a metabolic disorder called propionic acidemia, researchers used CRISPR-Cas12a to delete or disrupt a sequence that was activating a faulty splice site, restoring normal splicing and functional protein production in cells carrying the disease-causing variant.30PubMed Central. Targeted gene editing of PCCA pseudoexon using CRISPR-Cas12a for potential therapy in propionic acidemia Rather than replacing a broken gene wholesale, this approach fixes the splice signal so the cell’s own spliceosome processes the RNA correctly. It is a meeting point between the two meanings of “gene splicing,” using an artificial DNA-cutting tool to repair the instructions that guide a natural RNA-cutting machine.
This convergence is worth watching. As researchers get better at predicting which splice-site changes will produce which protein outcomes, the ability to precisely edit those signals with tools like CRISPR could open up therapies for a wide range of genetic diseases that trace back to a single misplaced cut in the RNA editing room.